5.3 Therapeutic Drug Monitoring (TDM), Narrow Therapeutic Index Drugs & Toxicities

5.3 Therapeutic Drug Monitoring (TDM), Narrow Therapeutic Index Drugs & Toxicities

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring drug concentrations in biological fluids (serum, plasma, or whole blood) to guide individualized dosage adjustments. By linking quantified drug exposure to clinical pharmacodynamics, TDM maximizes therapeutic efficacy while preventing concentration-dependent toxicities.

---

Core Principles and Indications for TDM

Routine therapeutic drug monitoring is neither necessary nor cost-effective for the majority of pharmaceuticals. TDM is strictly indicated when a therapeutic agent satisfies five cardinal criteria:

1. Narrow Therapeutic Index (NTI): A narrow margin exists between the minimum effective concentration ($MEC$) and the minimum toxic concentration ($MTC$). Small dosage changes can precipitate treatment failure or life-threatening toxicity.
2. Clear Concentration-Response Relationship: The pharmacological and toxicological effects correlate more strongly with circulating blood concentrations than with the administered dose.
3. Unpredictable Dose-Concentration Relationship: The drug displays substantial interindividual pharmacokinetic variability due to variable organ clearance, absorption differences, genetic polymorphisms, or capacity-limited non-linear elimination.
4. Absence of a Readily Measurable Clinical Surrogate Endpoint: Unlike antihypertensives (where blood pressure is directly measured) or anticoagulants (where INR or anti-Xa is measured), the desired clinical effect (e.g., seizure suppression, infection clearance, mood stabilization) cannot be assessed instantly with a routine bedside test.
5. Validated Analytical Assay Availability: Accurate, standardized laboratory assays with established therapeutic reference ranges must be clinically accessible.

Timing of Blood Sampling: Troughs, Peaks & Steady State

Drawing a blood sample at the incorrect time invalidates the laboratory result and can lead to dangerous dosing miscalculations:

• Trough Concentration ($C_{\text{min}}$): The lowest drug concentration during the dosing interval, drawn immediately prior to the next scheduled dose (ideally within $30\text{ minutes}$ before administration). Troughs assess drug accumulation, clearance, and safety.
• Peak Concentration ($C_{\text{max}}$): The highest drug concentration achieved after the completion of drug absorption and post-infusion distribution phase:
  • IV Aminoglycosides: Drawn $30\text{ minutes}$ after the end of a $30$-minute IV infusion (or 60 minutes after the start of infusion) to ensure distribution from the central compartment into tissue spaces is complete.
  • IV Vancomycin: Drawn $1\text{ to }2\text{ hours}$ after the end of the IV infusion to allow completion of the multi-compartment tissue distribution phase.
  • Oral Digoxin: Drawn at least $6\text{ to }8\text{ hours}$ post-dose (or immediately prior to the next dose) because digoxin exhibits a prolonged $6$- to $8$-hour tissue distribution phase into myocardial binding sites; levels drawn earlier reflect falsely elevated plasma levels that do not correlate with tissue response.
• Requirement for Steady State: Blood samples for routine dosage adjustments must be obtained at steady state (after $4\text{ to }5$ elimination half-lives of constant dosing), unless acute toxicity is suspected or early pharmacokinetic modeling (e.g., aminoglycoside Hartford nomogram) is specifically utilized.

Aminoglycosides: Gentamicin, Tobramycin & Amikacin

Aminoglycosides are bactericidal antibiotics targeting the bacterial $30\text{S}$ ribosomal subunit, primarily active against aerobic Gram-negative bacilli (Pseudomonas aeruginosa, Enterobacterales):

Pharmacodynamic Profile

• Concentration-Dependent Killing: Antibacterial efficacy is driven by the ratio of peak concentration to the minimum inhibitory concentration ($\text{Peak}/\text{MIC}$ or $C_{\text{max}}/\text{MIC}$). Optimal bactericidal killing requires a $C_{\text{max}}/\text{MIC} \ge 8\text{--}10$.
• Post-Antibiotic Effect (PAE): Aminoglycosides produce prolonged persistent suppression of bacterial growth for several hours even after serum concentrations drop far below the MIC.
• Adaptive Resistance Prevention: High transient peak concentrations prevent the emergence of adaptive bacterial resistance.

Extended-Interval (Once-Daily) Dosing vs. Traditional Dosing

Toxicities

1. Nephrotoxicity: Non-oliguric acute tubular necrosis (ATN) resulting from progressive accumulation in proximal tubular lysosomes. Characterized by rising serum creatinine, granular casts, and proteinuria. Typically reversible upon drug cessation.
2. Ototoxicity: Accumulates in the endolymph and perilymph of the inner ear, destroying sensory hair cells. Manifests as vestibular toxicity (vertigo, ataxia, loss of balance) and cochlear toxicity (tinnitus, irreversible high-frequency sensorineural hearing loss). Frequently irreversible!
3. Neuromuscular Blockade: Rare, life-threatening inhibition of presynaptic acetylcholine release and postsynaptic receptor blockade, precipitating respiratory arrest; exacerbated by neuromuscular blockers or myasthenia gravis (reversal: IV calcium gluconate).

---

Vancomycin: The Modern AUC/MIC Paradigm

Vancomycin is a glycopeptide antibiotic that binds D-Ala-D-Ala terminals of peptidoglycan precursors, inhibiting cell wall synthesis in Gram-positive organisms (including Methicillin-Resistant Staphylococcus aureus [MRSA]).

PK/PD Efficacy Target: $\text{AUC}_{24}/\text{MIC}$

Vancomycin exhibits time-dependent, concentration-independent bactericidal activity. The primary pharmacokinetic parameter predicting clinical success and bacterial eradication is the ratio of the $24$-hour area under the curve to the minimum inhibitory concentration:

$\frac{\text{AUC}_{24}}{\text{MIC}} = 400\text{ to }600\text{ mg}\cdot\text{h/L}$

(Assuming a standard broth microdilution $\text{MIC} \le 1\text{ mg/L}$).

Vancomycin Toxicities & Infusion Reactions

• Nephrotoxicity: Acute tubular necrosis and acute interstitial nephritis; risk escalates with AUC $> 600\text{ mg}\cdot\text{h/L}$, sustained troughs $>20\text{ mg/L}$, therapy $>7$ days, and concurrent nephrotoxins (especially piperacillin/tazobactam).
• Vancomycin Infusion Reaction (historically "Red Man Syndrome"): An immediate, non-IgE-mediated, rate-dependent pseudoallergic reaction caused by direct degranulation of mast cells and basophils, releasing histamine. Symptoms include erythematous flushing, pruritus, tingling, and an erythematous maculopapular rash across the face, neck, and upper torso, occasionally accompanied by hypotension.
  • Prevention & Management: Infuse vancomycin slowly at a rate $\le 1,000\text{ mg}$ over at least $60\text{ minutes}$ (or $\le 10\text{ mg/min}$ for doses $>1,000\text{ mg}$). If the reaction occurs, stop the infusion, administer an oral or IV $\text{H}_1$-antihistamine (diphenhydramine $50\text{ mg}$) and $\text{H}_2$-antagonist (famotidine), wait for symptom resolution, and restart the infusion at half the original rate.

Phenytoin: Protein Binding & The Sheiner-Tozer Correction

Phenytoin is a narrow therapeutic index hydantoin antiseizure medication used in focal and generalized status epilepticus:

• Therapeutic Reference Range: Total Phenytoin $= 10\text{ to }20\text{ mg/L}$ ($40\text{ to }80\ \mu\text{mol/L}$).
• Free (Unbound) Phenytoin Range: Free Phenytoin $= 1\text{ to }2\text{ mg/L}$ ($4\text{ to }8\ \mu\text{mol/L}$).

Protein Binding Displacement Dynamics

In healthy adults, phenytoin is approximately $90\%$ bound to plasma albumin; only the remaining $10\%$ free fraction ($f_u = 0.10$) cross the blood-brain barrier to exert anticonvulsant activity and undergo hepatic metabolism. In patients with hypoalbuminemia (serum albumin $< 40\text{ g/L}$ or $< 4.0\text{ g/dL}$) or end-stage renal disease (ESRD), the free fraction increases substantially. The measured total phenytoin level appears falsely low, while the active free level remains therapeutic or toxic.

The Sheiner-Tozer Equations

When free phenytoin levels are unavailable, pharmacists calculate the adjusted (corrected) total phenytoin concentration:

In Canadian SI units (Albumin in $\text{g/L}$, where normal albumin is $\approx 40\text{ g/L}$):

$C_{\text{corrected}} = \frac{C_{\text{measured}}}{0.02 \times \text{Albumin (g/L)} + 0.1}$

When Albumin is reported in conventional units ($\text{g/dL}$):

$C_{\text{corrected}} = \frac{C_{\text{measured}}}{0.2 \times \text{Albumin (g/dL)} + 0.1}$

In End-Stage Renal Disease ($\text{CrCl} < 15\text{ mL/min}$ or hemodialysis), uremic toxins displace phenytoin from albumin binding sites, further reducing affinity:

$C_{\text{corrected, ESRD}} = \frac{C_{\text{measured}}}{0.01 \times \text{Albumin (g/L)} + 0.1} \quad \left(\text{or } \frac{C_{\text{measured}}}{0.1 \times \text{Albumin (g/dL)} + 0.1}\right)$

Concentration-Dependent Phenytoin Toxicity

• $> 20\text{ mg/L}$ ($> 80\ \mu\text{mol/L}$): Lateral gaze nystagmus
• $> 30\text{ mg/L}$ ($> 120\ \mu\text{mol/L}$): Ataxia, slurred speech, dysarthria, nausea, vomiting
• $> 40\text{ mg/L}$ ($> 160\ \mu\text{mol/L}$): Lethargy, stupor, confusion, coma, paradoxical encephalopathic seizures
• Chronic Effects: Gingival hyperplasia, hirsutism, peripheral neuropathy, coarsening of facial features, osteomalacia, folate deficiency.

---

Lithium

Lithium carbonate is a monovalent cation used in bipolar affective disorder for acute mania and maintenance mood stabilization:

• Therapeutic Reference Range:
  • Acute Mania: $0.8\text{ to }1.2\text{ mmol/L}$
  • Maintenance Therapy: $0.6\text{ to }0.8\text{ mmol/L}$ (rarely up to $1.0\text{ mmol/L}$)
• Sampling Timing: Standard 12-hour trough drawn in the morning, exactly 12 hours after the evening dose at steady state.

Renal Mechanics and Drug Interactions

Lithium is not metabolized; it is eliminated entirely by renal glomerular filtration. In the renal proximal tubule, lithium is handled identically to sodium, with $80\%$ of filtered lithium reabsorbed alongside sodium:

• Sodium Depletion / Volume Contraction: When the body experiences sodium or water depletion (dehydration, vomiting, diarrhea, intense sweating, sodium-restricted diet), the proximal tubule compensatorily increases sodium and water reabsorption, simultaneously reabsorbing lithium, rapidly driving serum lithium into toxic ranges.

Symptoms of Lithium Toxicity

• Mild ($1.5\text{--}2.0\text{ mmol/L}$): Coarse hand tremor, persistent diarrhea, nausea, vomiting, muscle weakness, lethargy.
• Moderate ($2.0\text{--}2.5\text{ mmol/L}$): Hyperreflexia, ataxia, dysarthria, blurred vision, clonic movements, confusion.
• Severe ($> 2.5\text{ mmol/L}$): Delirium, seizures, stupor, cardiovascular collapse, permanent cerebellar and cognitive impairment (SILENT syndrome—Syndrome of Irreversible Lithium-Effectuated Neurotoxicity).
• Management: Aggressive IV hydration with Normal Saline ($0.9\%\ \text{NaCl}$) to restore intravascular volume and promote renal lithium clearance. The EXTRIP workgroup recommends hemodialysis when kidney function is impaired and lithium exceeds $4.0\text{ mmol/L}$, or when there is decreased consciousness, seizures or a life-threatening dysrhythmia at any level. It suggests dialysis when lithium exceeds $5.0\text{ mmol/L}$, when there is significant confusion, or when lithium is expected to take more than 36 hours to fall below $1.0\text{ mmol/L}$ with optimal management.

---

Digoxin

Digoxin is a cardiac glycoside that inhibits myocardial $\text{Na}^+/\text{K}^+$-ATPase, increasing intracellular calcium to enhance inotropy and vagally blunting AV node conduction:

• Therapeutic Reference Range:
  • Heart Failure with Reduced Ejection Fraction (HFrEF): $0.5\text{ to }0.9\text{ ng/mL}$ ($0.6\text{ to }1.2\text{ nmol/L}$). Levels $>1.0\text{ ng/mL}$ provide zero additional inotropic benefit but significantly increase all-cause mortality!
  • Atrial Fibrillation Rate Control: $0.8\text{ to }2.0\text{ ng/mL}$ ($1.0\text{ to }2.6\text{ nmol/L}$).
• Sampling Timing: Serum levels must be drawn at least $6\text{ to }8\text{ hours}$ post-dose to allow complete myocardial tissue equilibration.

The Electrolyte Triad Potentiating Digoxin Toxicity

1. Hypokalemia: Extracellular potassium and digoxin compete for the same binding site on the $\text{Na}^+/\text{K}^+$-ATPase pump. When serum potassium falls below $4.0\text{ mmol/L}$, more ATPase sites are left open for digoxin binding, precipitating severe life-threatening digitalis toxicity even when serum digoxin levels are within the normal reference range!
2. Hypomagnesemia: Impairs $\text{Na}^+/\text{K}^+$-ATPase function, directly promoting digitalis arrhythmias.
3. Hypercalcemia: Synergizes with digoxin to overload intracellular cardiac calcium stores, precipitating fatal ventricular tachyarrhythmias.

Digoxin Toxicity Manifestations

• Gastrointestinal: Anorexia (earliest sign), nausea, vomiting, abdominal discomfort.
• Visual: Xanthopsia (yellow-green color halos around lights), photophobia, blurred vision, scotomas.
• Cardiac: Sinus bradycardia, high-degree AV block, premature ventricular contractions (bigeminy), bidirectional ventricular tachycardia, ventricular fibrillation. Classic ECG sign: "scooped" ST-segment depression (digitalis effect, not necessarily toxicity).

Clinical Toxicology and Specific Reversal Antidotes

When acute drug overdose or life-threatening adverse drug events occur, pharmacists must immediately recommend evidence-based reversal strategies and specific antidotes: